Monoamine Oxidase Inhibitors (Maois) Interactions

Contraindicated with amitriptyline; see contraindications section.

Source: NLP:amitriptyline hydrochloride

Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes may occur when combined with MAOIs.

Source: NLP:atomoxetine

Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes when combined with MAOIs.

Source: NLP:atomoxetine hydrochloride

Hypertensive crises have resulted when sympathomimetic amines used concomitantly or within 14 days following use of monoamine oxidase inhibitors.

Source: NLP:benzphetamine hydrochloride

Hyperpyrexia, hypotension, and death reported with coadministration. MAO inhibitors prolong/intensify anticholinergic effects and enhance pseudoephedrine effect.

Source: NLP:brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide

Concomitant administration should be avoided. MAO inhibitors prolong and intensify anticholinergic effects of brompheniramine and may enhance pseudoephedrine effects.

Source: NLP:brompheniramine maleate, pseudoephedrine hydrochloride,

Increased risk of serotonin syndrome and/or elevated blood pressure. Contraindicated within 14 days of stopping either drug.

Source: NLP:buspirone hydrochloride

MAOIs prolong and intensify the anticholinergic (drying) effects of carbinoxamine. Do not use concomitantly.

Source: NLP:carbinoxamine maleate

Contraindicated use with citalopram per CONTRAINDICATIONS and WARNINGS sections.

Source: NLP:citalopram

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking MAOIs.

Source: NLP:citalopram hydrobromide

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Source: NLP:dexmethylphenidate hydrochloride

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, and aortic dissection. Do not use concomitantly or within 14 days of MAOI discontinuation.

Source: NLP:dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate

Do not use NUEDEXTA with MAOIs or in patients who have taken MAOIs within the preceding 14 days.

Source: NLP:dextromethorphan hydrobromide and quinidine sulfate

Hypertension may result when diethylpropion is used with MAO inhibitors due to monoamine interaction.

Source: NLP:diethylpropion hydrochloride

MAOIs may interact with diphenoxylate and precipitate hypertensive crisis. Avoid use and monitor for signs including headache, hyperthermia, and hypertension.

Source: NLP:diphenoxylate hydrochloride and atropine sulfate

MAOIs are contraindicated with escitalopram due to risk of serotonin syndrome.

Source: NLP:escitalopram

Concomitant use with MAOIs is contraindicated due to risk of serious adverse reactions including serotonin syndrome.

Source: NLP:escitalopram oxalate

Contraindicated combination with fluoxetine due to risk of serotonin syndrome.

Source: NLP:fluoxetine

MAOIs are contraindicated with fluoxetine due to risk of serious adverse effects.

Source: NLP:fluoxetine hydrochloride

Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Source: NLP:hydrocodone polistirex and chlorpheniramine polistirex

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI treatment.

Source: NLP:levomilnacipran hydrochloride

Linezolid is a reversible, nonselective inhibitor of monoamine oxidase and is contraindicated with MAOIs due to potential serious interactions.

Source: NLP:linezolid

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, and aortic dissection. Contraindicated within 14 days of MAOI discontinuation.

Source: NLP:methylphenidate

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Source: NLP:methylphenidate hydrochloride

Increased risk of hypertension. Avoid concomitant use.

Source: NLP:metoclopramide

Increased risk of hypertension. Avoid concomitant use.

Source: NLP:metoclopramide hydrochloride

Concomitant use increases risk of serotonin syndrome. Use of MAOIs with SAVELLA or within 5 days of stopping SAVELLA is contraindicated.

Source: NLP:milnacipran hydrochloride

MAOIs are contraindicated with olanzapine and fluoxetine combination due to risk of serious adverse effects.

Source: NLP:olanzapine and fluoxetine

Contraindicated due to risk of serotonin syndrome.

Source: NLP:paroxetine

Concomitant use is contraindicated due to risk of serotonin syndrome.

Source: NLP:paroxetine hydrochloride hemihydrate

Concomitant use of phentermine with MAOIs increases the risk of hypertensive crisis. Contraindicated during MAOI treatment and within 14 days of stopping an MAOI.

Source: NLP:phentermine and topiramate extended-release

Contraindicated during or within 14 days of MAOI administration due to risk of hypertensive crisis.

Source: NLP:phentermine hydrochloride

Hyperpyrexia, hypotension, and death reported with co-administration. Increased extrapyramidal effects when MAO inhibitors used with phenothiazines. Concomitant administration should be avoided.

Source: NLP:promethazine hydrochloride and dextromethorphan hydrobromide

May manifest as serotonin syndrome or opioid toxicity. Not recommended for patients taking MAOIs or within 14 days of stopping treatment.

Source: NLP:remifentanil hydrochloride

Rizatriptan is contraindicated in patients taking non-selective MAO inhibitors.

Source: NLP:rizatriptan benzoate

Concomitant use increases risk of serotonin syndrome. Sertraline HCl Capsules is contraindicated in patients taking MAOIs.

Source: NLP:sertraline hydrochloride

Do not administer SUNOSI concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment. Concomitant use may increase risk of hypertensive reaction with serious outcomes including death, stroke, myocardial infarction, and aortic dissection.

Source: NLP:solriamfetol

MAO-A inhibitors increase systemic exposure of sumatriptan 7-fold. Use is contraindicated.

Source: NLP:sumatriptan and naproxen sodium

Tetrabenazine is contraindicated in patients taking MAOIs. Minimum 14 days must elapse after discontinuing MAOI before starting tetrabenazine.

Source: NLP:tetrabenazine

Concomitant use increases risk of serotonin syndrome. Contraindicated in patients taking MAOIs.

Source: NLP:venlafaxine hydrochloride

Concomitant use increases risk of serotonin syndrome. Vilazodone hydrochloride is contraindicated in patients taking MAOIs.

Source: NLP:vilazodone hydrochloride

MAOIs may potentiate the effects of epinephrine.

Source: NLP:adrenalin (epinephrine)

May potentiate cardiovascular effects of albuterol. Use with extreme caution or consider alternative therapy.

Source: NLP:albuterol sulfate

Use with extreme caution due to potential cardiovascular effects.

Source: NLP:albuterol sulfate and budesonide

May potentiate cardiovascular effects of arformoterol. Should be administered with extreme caution.

Source: NLP:arformoterol tartrate

May produce severe, prolonged hypertension when combined with local anesthetic solutions containing epinephrine.

Source: NLP:articaine hydrochloride and epinephrine

May produce severe, prolonged hypertension when local anesthetic solutions containing epinephrine are administered to patients receiving MAOIs.

Source: NLP:articaine hydrochloride, epinephrine bitartrate

Use of atropine with MAOIs is generally not recommended due to potential to precipitate hypertensive crisis.

Source: NLP:atropine sulfate monohydrate

May produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Source: NLP:betamethasone sodium phosphate and betamethasone acetate, bupivacaine hydrochloride, povidine iodine

May result in increased hypotension when used with brimonidine tartrate and timolol maleate.

Source: NLP:brimonidine tartrate and timolol maleate

May potentiate the effect of formoterol on the vascular system. Use with extreme caution or within 2 weeks of discontinuation.

Source: NLP:budesonide and formoterol fumarate

Administration may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Source: NLP:bupivacaine hydrochloride

May produce severe, prolonged hypertension. Concurrent use should generally be avoided; if necessary, careful hemodynamic monitoring is essential.

Source: NLP:bupivacaine hydrochloride and epinephrine bitartrate

Increased risk of hypertensive reactions when used concomitantly with bupropion.

Source: NLP:bupropion hydrochloride

MAO inhibitors may enhance the CNS effects of butalbital.

Source: NLP:butalbital, acetaminophen, and caffeine

CNS effects of butalbital may be enhanced by MAO inhibitors.

Source: NLP:butalbital, aspirin, and caffeine

May increase risk of hypotension and/or severe bradycardia through catecholamine depletion combined with beta-blockade.

Source: NLP:carvedilol

Catecholamine-depleting agents that may increase risk of hypotension and severe bradycardia when combined with carvedilol.

Source: NLP:carvedilol phosphate

MAOIs potentiate CNS-depressant action of clonazepam.

Source: NLP:clonazepam

Actions of benzodiazepines may be potentiated by monoamine oxidase inhibitors.

Source: NLP:clorazepate dipotassium

Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors.

Source: NLP:cocaine hydrochloride nasal

Administration with Bupivacaine Hydrochloride and Epinephrine may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Source: NLP:dexamethasone sodium phosphate, bupivacaine hydrochloride, povidine iodine

Inhibition of MAO prolongs and potentiates dopamine effects. Initial dopamine dose should not exceed 1/10 of usual dose if given within 2-3 weeks of MAO inhibitor treatment.

Source: NLP:dopamine hydrochloride

Potentiate pressor effects of epinephrine.

Source: NLP:epinephrine

Effects of epinephrine may be potentiated by monoamine oxidase inhibitors.

Source: NLP:epinephrine 0.15 pediatrics

Use with extreme caution; may potentiate salmeterol effects on the vascular system.

Source: NLP:fluticasone propionate and salmeterol xinafoate

May potentiate formoterol effects on vascular system. Use with extreme caution and avoid within 2 weeks of discontinuation.

Source: NLP:budesonide and formoterol fumarate dihydrate

Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Source: NLP:hydrocodone bitartrate and homatropine methylbromide

Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping an MAOI.

Source: NLP:hydrocodone bitartrate and homatropine methylbromide oral solution

Extreme caution advised; action of albuterol on cardiovascular system may be potentiated. Should not be used within 2 weeks of MAOi discontinuation.

Source: NLP:ipratropium bromide and albuterol sulfate

May potentiate clinical response of isoproterenol; hemodynamic parameters may be significantly affected.

Source: NLP:isoproterenol hydrochloride

Levalbuterol should be administered with extreme caution to patients being treated with MAOIs or within 2 weeks of discontinuation due to risk of potentiating cardiovascular effects.

Source: NLP:levalbuterol

Levalbuterol should be administered with extreme caution to patients on MAOIs or within 2 weeks of discontinuation due to potential potentiation of cardiovascular effects.

Source: NLP:levalbuterol hydrochloride

May potentiate effects of levalbuterol on the cardiovascular system. Use with extreme caution or consider alternative therapy.

Source: NLP:levalbuterol tartrate

Concomitant use has resulted in serotonin syndrome.

Source: NLP:levorphanol tartrate

Administration of lidocaine solutions containing epinephrine may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Source: NLP:lidocaine hydrochloride

May produce severe prolonged hypotension or hypertension. Concurrent use should generally be avoided; careful monitoring essential if necessary.

Source: NLP:lidocaine hydrochloride and epinephrine bitartrate

Concomitant administration can precipitate serotonin syndrome. Monitor for signs and symptoms, particularly during lithium initiation.

Source: NLP:lithium carbonate

Administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving MAOIs may produce severe, prolonged hypertension.

Source: NLP:lidocaine, kenalog, povidone iodine

Concurrent use with vasopressor-containing local anesthetic solutions may produce severe, prolonged hypertension.

Source: NLP:mepivacaine hydrochloride

Concomitant use may result in serotonin syndrome. Carefully observe patient during treatment initiation and dosage modification; discontinue metaxalone if serotonin syndrome occurs.

Source: NLP:metaxalone

Can potentiate the effects of methadone. Avoid concomitant use or within 14 days of stopping MAOI treatment.

Source: NLP:methadone hydrochloride

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Source: NLP:methylene blue

Administration of Bupivacaine Hydrochloride and Epinephrine to patients receiving MAOIs may produce severe, prolonged hypertension. Concurrent use should generally be avoided.

Source: NLP:methylprednisolone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidine iodine, isopropyl alcohol

Catecholamine-depleting drugs with additive effect; may cause hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Source: NLP:metoprolol tartrate

Catecholamine-depleting drugs that may have additive effect with metoprolol, increasing risk of hypotension or bradycardia.

Source: NLP:metoprolol tartrate and hydrochlorothiazide

Co-administration can cause severe, prolonged hypertension. Monitor for hypertension if administration cannot be avoided.

Source: NLP:norepinephrine bitartrate

Can potentiate the effects of oxycodone. Avoid concomitant use or within 14 days of stopping MAOI treatment.

Source: NLP:oxycodone hydrochloride

MAOI interactions may manifest as serotonin syndrome or opioid toxicity including respiratory depression and coma.

Source: NLP:oxymorphone hydrochloride

Concomitant use may cause CNS excitation and hypertension through effects on catecholamines. Avoid use within 14 days of MAOI discontinuation.

Source: NLP:pentazocine and naloxone

MAOIs prolong the effects of barbiturates by inhibiting barbiturate metabolism.

Source: NLP:phenobarbital

Agonistic effects increase phenylephrine blood pressure effect.

Source: NLP:phenylephrine hydrochloride

May produce severe, prolonged hypotension or hypertension; concurrent use should generally be avoided.

Source: NLP:prilocaine hcl and epinephrine

Concomitant use with MAOIs and phenothiazines may result in increased incidence of extrapyramidal effects; possibility should be considered.

Source: NLP:promethazine hydrochloride

MAOI with promethazine increases incidence of extrapyramidal effects. MAOI with phenylephrine may cause acute hypertensive crisis with potentiated cardiac pressor response.

Source: NLP:promethazine hydrochloride and phenylephrine hydrochloride

Terbutaline action on the vascular system may be potentiated when used with MAOIs or within 2 weeks of discontinuation.

Source: NLP:terbutaline sulfate

MAO inhibitors may potentiate the action of adrenergic agonists on the cardiovascular system. Use with extreme caution.

Source: NLP:tiotropium bromide and olodaterol

Severe, prolonged hypertension may occur with local anesthetic solutions containing epinephrine.

Source: NLP:bupivacaine hydrochloride, lidocaine hydrochloride, triamcinolone acetonide, povidine iodine

Use with extreme caution. May potentiate vilanterol's effect on cardiovascular system, increasing risk of adverse cardiac events.

Source: NLP:umeclidinium bromide and vilanterol trifenatate

Caution should be used when concomitantly administering MAO inhibitors and armodafinil.

Source: NLP:armodafinil

May potentiate the effects of epinephrine.

Source: NLP:auvi-q

MAO inhibitors may interfere with brimonidine metabolism, potentially resulting in increased systemic side effects such as hypotension.

Source: NLP:brimonidine

May interfere with brimonidine metabolism and potentially result in increased systemic side effects such as hypotension; caution advised.

Source: NLP:brimonidine tartrate

MAO inhibitors may enhance the CNS effects of butalbital.

Source: NLP:butalbital and acetaminophen

MAO inhibitors may theoretically increase brimonidine metabolism interference and result in increased systemic hypotension. Caution advised.

Source: NLP:carbachol and brimonidine tartrate

Augments the pressor effect of ephedrine. Carefully monitor blood pressure.

Source: NLP:ephedrine sulfate

May potentiate the action of estazolam; careful consideration of CNS effects needed.

Source: NLP:estazolam

May interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.

Source: NLP:fluorodopa f18

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

Source: NLP:glyburide

May increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

Source: NLP:glimepiride

MAOIs may potentiate hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia when initiated or withdrawn.

Source: NLP:glipizide

May potentiate hypoglycemic action of glyburide; monitor closely for hypoglycemia.

Source: NLP:glyburide and metformin hydrochloride

May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.

Source: NLP:glyburide-metformin hydrochloride

Additive adverse effects from cholinergic blockade may occur when combined with hyoscyamine sulfate.

Source: NLP:hyoscyamine sulfate

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart-szjj

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Source: NLP:insulin degludec

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Source: NLP:insulin glargine

May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin glulisine

May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin human

May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Source: NLP:insulin lispro-aabc

Concurrent use with hyoscyamine may intensify antimuscarinic side effects.

Source: NLP:methenamine, sodium phosphate, monobasic, anhydrous, phenyl salicylate, methylene blue and hyoscyamine sulfate

Catecholamine-depleting drugs with additive effect. May cause hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Source: NLP:metoprolol

Catecholamine-depleting drugs may have additive effect with metoprolol, causing hypotension or marked bradycardia with vertigo, syncope, or postural hypotension.

Source: NLP:metoprolol succinate

Catecholamine-depleting drug may have additive effect with metoprolol, increasing risk of hypotension or marked bradycardia.

Source: NLP:metoprolol succinate er tablets

Caution should be used when concomitantly administering MAO inhibitors and modafinil.

Source: NLP:modafinil

MAO inhibitors can affect metabolism and uptake of circulating amines; caution is advised.

Source: NLP:oxymetazoline hydrochloride

MAOIs prolong barbiturate effects by inhibiting barbiturate metabolism.

Source: NLP:pentobarbital sodium

MAOIs prolong the effects of barbiturates by inhibiting barbiturate metabolism, resulting in additive CNS depressant effects.

Source: NLP:phenobarbital sodium

May enhance neuromuscular blocking effect through plasma cholinesterase inhibition.

Source: NLP:succinylcholine chloride